Frontlight ResearchEarly access
Childhood cancers trials in China
609 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 2/3Taking peopleBrentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
- Where
- Shanghai
- Age
- 2 years to 35 years
- People
- 96
- Run by
- Children's Cancer Group, China
See details and how to joinNCT06563245 - No phaseNot yet taking people in ChinaHEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors
- Where
- Hangzhou, Ningbo
- Age
- 1 year to 21 years
- People
- 400
- Run by
- The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07483749 - Phase 1Taking peopleBY002 IIT Study in R/R Acute Leukemia
- Where
- Suzhou
- Age
- 16 years and over
- People
- 18
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07270770 - Phase 1/2Taking peopleApatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
- Where
- Beijing
- Age
- 12 years to 65 years
- People
- 56
- Run by
- Peking University People's Hospital
See details and how to joinNCT07479732 - No phaseTaking peopleStandardized Nutritional Management of Pediatric Patients With Solid Tumors
- Where
- Shanghai
- Age
- Up to 18 years
- People
- 400
- Run by
- Children's Hospital of Fudan University
See details and how to joinNCT06730204 - Early phase 1Taking peopleA Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults
- Where
- Wuhan
- Age
- 12 years to 75 years
- People
- 18
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07470073 - Phase 1/2Taking peopleCD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
- Where
- Beijing, Chengdu, Shanghai
- Age
- 1 year to 70 years
- People
- 54
- Run by
- Beijing GoBroad Hospital
See details and how to joinNCT06316856 - No phaseTaking peopleClinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
- Where
- Beijing
- Age
- 1 year to 70 years
- People
- 353
- Run by
- Beijing GoBroad Hospital
See details and how to joinNCT06343090 - No phaseTaking peopleIntegrating Multimodal AI to Predict Treatment Response and Refine Risk Stratification in Esophageal Cancer (Radiogenomics-Esophagus)
- Where
- Wuhan
- People
- 1,500
- Run by
- Shu Peng
See details and how to joinNCT07354295 - No phaseNot yet taking people in ChinaNUDT15/TPMT Multi-gene Guided 6-MP Dosing in Childhood ALL Maintenance Therapy
- Where
- Hangzhou
- Age
- 1 year to 18 years
- People
- 110
- Run by
- The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07462299 - Phase 1Taking peopleSafety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
- Where
- Beijing
- Age
- 1 year to 18 years
- People
- 48
- Run by
- Beijing GoBroad Hospital
See details and how to joinNCT06326008 - Phase 2Not yet taking people in ChinaLiposomal Irinotecan in Combination With Temozolomide and Bevacizumab in Patients With Advanced STS
- Where
- Hangzhou
- Age
- 14 years and over
- People
- 24
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07457775 - No phaseTaking peopleConstruction of AI Model for Precision Imaging Diagnosis of Cranial Diseases
- Where
- Wuhan
- People
- 1,000
- Run by
- Tongji Hospital
See details and how to joinNCT07446842 - Phase 2Not yet taking people in ChinaIFN-α in Relapse Prevention.
- Where
- Beijing
- Age
- 12 years to 65 years
- People
- 100
- Run by
- Peking University People's Hospital
See details and how to joinNCT07449286 - No phaseTaking peopleClinical Translation Research on a Multi-omics Breast Cancer Distant Metastasis Prediction Model Empowered by Artificial Intelligence
- Where
- Hangzhou
- People
- 2,000
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07252986 - No phaseTaking peopleRW Study of Adjuvant Radiotherapy in Locally Advanced Thyroid Cancer
- Where
- Shanghai
- Age
- 14 years to 80 years
- People
- 80
- Run by
- Fudan University
See details and how to joinNCT06524167 - Phase 3Taking peopleSelective Neck Dissection Versus Modified Neck Dissection in PTC
- Where
- Shanghai
- Age
- 14 years to 80 years
- People
- 250
- Run by
- Fudan University
See details and how to joinNCT06554652 - Phase 3Taking peopleAdjuvant Radiotherapy in High Risk Locally Advanced DTC
- Where
- Shanghai
- Age
- 14 years to 80 years
- People
- 124
- Run by
- Fudan University
See details and how to joinNCT06558981 - Phase 3Taking peopleCD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
- Where
- Beijing
- Age
- 3 years to 79 years
- People
- 70
- Run by
- Peking University People's Hospital
See details and how to joinNCT07441291 - No phaseTaking peoplePrimary Tumor Research and Outcomes Network
- Where
- Beijing
- People
- 1,350 worldwide
- Run by
- AO Innovation Translation Center
See details and how to joinNCT02790983 - No phaseTaking peopleCIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction
- Where
- Beijing
- Age
- 1 year to 39 years
- People
- 213
- Run by
- Beijing GoBroad Hospital
See details and how to joinNCT06389305 - No phaseTaking peopleResponse to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
- Where
- Fuzhou
- Age
- 14 years to 80 years
- People
- 120
- Run by
- Fujian Medical University
See details and how to joinNCT07419932 - Phase 1/2Taking peopleBiomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
- Where
- Beijing
- Age
- 8 years to 85 years
- People
- 85
- Run by
- Essen Biotech
See details and how to joinNCT07410494 - Phase 1/2Taking peopleEBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
- Where
- Beijing
- People
- 83
- Run by
- Essen Biotech
See details and how to joinNCT07410676 - No phaseEnrolling by invitationAI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH Abnormalities
- Where
- Wuhan
- People
- 10
- Run by
- Fuling Zhou
See details and how to joinNCT07410403